[go: up one dir, main page]

ES486990A1 - Un procedimiento para la preparacion de un derivado de car- boestirilo - Google Patents

Un procedimiento para la preparacion de un derivado de car- boestirilo

Info

Publication number
ES486990A1
ES486990A1 ES486990A ES486990A ES486990A1 ES 486990 A1 ES486990 A1 ES 486990A1 ES 486990 A ES486990 A ES 486990A ES 486990 A ES486990 A ES 486990A ES 486990 A1 ES486990 A1 ES 486990A1
Authority
ES
Spain
Prior art keywords
compounds
present
fighting
attitude
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES486990A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd
Publication of ES486990A1 publication Critical patent/ES486990A1/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • C07D215/28—Alcohols; Ethers thereof with halogen atoms or nitro radicals in positions 5, 6 or 7

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Anesthesiology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

En lo que se refiere a las actividades de control nervioso central, los compuestos de la presente invención se caracterizan porque presentan fuertes actividades de control sobre la actitud de lucha de ratones que han permanecido aislados durante largos periodos de tiempo. Así. En comparación con el Diazepam, que es un compuesto con una reconocida elevada actividad de este tipo, los compuestos de la presente invención tiene un importante efecto de control sobre la actitud de lucha de ratones. Por tanto, los compuestos presentes son bastantes útiles particularmente como sedantes, fármacos anti-ansiedad, y fármacos anti-psicosis maniaco depresiva. Además los compuestos de la presente invención aumentan fuertemente la anestesia y el sueño cuando se utilizan en combinación con anestésicos e hipnóticos.
ES486990A 1978-03-30 1979-12-17 Un procedimiento para la preparacion de un derivado de car- boestirilo Expired ES486990A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP3778378A JPS54130587A (en) 1978-03-30 1978-03-30 Carbostyryl derivative

Publications (1)

Publication Number Publication Date
ES486990A1 true ES486990A1 (es) 1980-10-01

Family

ID=12507080

Family Applications (4)

Application Number Title Priority Date Filing Date
ES479134A Expired ES479134A1 (es) 1978-03-30 1979-03-30 Un procedimiento para la preparacion de un derivado de car- boestirilo.
ES486991A Expired ES486991A1 (es) 1978-03-30 1979-12-17 Un procedimiento para la preparacion de un derivado de car- boestirilo
ES486992A Expired ES486992A1 (es) 1978-03-30 1979-12-17 Un procedimiento para la preparacion de un derivado de car- boestirilo
ES486990A Expired ES486990A1 (es) 1978-03-30 1979-12-17 Un procedimiento para la preparacion de un derivado de car- boestirilo

Family Applications Before (3)

Application Number Title Priority Date Filing Date
ES479134A Expired ES479134A1 (es) 1978-03-30 1979-03-30 Un procedimiento para la preparacion de un derivado de car- boestirilo.
ES486991A Expired ES486991A1 (es) 1978-03-30 1979-12-17 Un procedimiento para la preparacion de un derivado de car- boestirilo
ES486992A Expired ES486992A1 (es) 1978-03-30 1979-12-17 Un procedimiento para la preparacion de un derivado de car- boestirilo

Country Status (21)

Country Link
US (2) US4734416A (es)
JP (1) JPS54130587A (es)
AT (1) AT376432B (es)
AU (1) AU515531B2 (es)
BE (1) BE875174A (es)
CA (1) CA1117110A (es)
CH (2) CH641455A5 (es)
DE (2) DE2953723C2 (es)
DK (1) DK158225C (es)
ES (4) ES479134A1 (es)
FI (1) FI70704C (es)
FR (1) FR2421174A1 (es)
GB (1) GB2017701B (es)
IT (1) IT1119284B (es)
MX (1) MX5862E (es)
NL (1) NL183189C (es)
NO (1) NO151321C (es)
PT (1) PT69422A (es)
SE (1) SE434945B (es)
SU (2) SU1140687A3 (es)
ZA (1) ZA791516B (es)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2827566A1 (de) * 1978-06-23 1980-01-10 Boehringer Mannheim Gmbh 1,2-dihydro-chinolin-2-on-derivate und verfahren zu ihrer herstellung
DE3034237A1 (de) * 1979-09-18 1981-04-16 Otsuka Pharmaceutical Co. Ltd., Tokyo Carbostyrilderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende, antihistaminisch wirkende mittel
PH17194A (en) * 1980-03-06 1984-06-19 Otsuka Pharma Co Ltd Novel carbostyril derivatives,and pharmaceutical composition containing the same
JPS57193461A (en) * 1981-05-22 1982-11-27 Otsuka Pharmaceut Co Ltd Benzazepine derivative
CN85108214A (zh) * 1984-11-22 1986-08-20 赫彻斯特股份公司 新的取代的苯基哌嗪衍生物及其药物的制造方法
JPS6129331A (ja) * 1985-03-13 1986-02-10 アラ−ガン・ハンフリ− 検眼装置
DK588486A (da) * 1985-12-09 1987-06-10 Otsuka Pharma Co Ltd Anvendelse af en forbindelse til behandling af hypoxi
DK167187A (da) * 1986-04-02 1987-10-03 Otsuka Pharma Co Ltd Carbostyrilderivater og salte deraf, fremgangsmaade til fremstilling af saadanne forbindelser og laegemiddel indeholdende disse
KR940000785B1 (ko) * 1986-04-02 1994-01-31 오오쓰까세이야꾸 가부시끼가이샤 카르보스티릴 유도체 및 그의 염의 제조 방법
JPH0696555B2 (ja) * 1986-07-31 1994-11-30 大塚製薬株式会社 カルボスチリル誘導体
DK397387A (da) * 1986-07-31 1988-02-01 Otsuka Pharma Co Ltd Carbostyrilderivater og salte deraf samt fremgangsmaade til fremstilling af saadanne forbindelser
US4803203A (en) * 1986-11-05 1989-02-07 Warner-Lambert Company Phenyl and heterocyclic piperazinyl alkoxy-benzheterocyclic compounds as antipsychotic agents
JPS63141967A (ja) * 1986-11-21 1988-06-14 エイ・エッチ・ロビンス・カンパニー・インコーポレーテッド 抗アレルギー薬として有用な１−アリールオキシー４−［（４−アリール）−１−ピペラジニル］−２−ブタノール
FR2637591B1 (fr) * 1988-10-11 1992-10-23 Synthelabo Derives de quinoleinone, leur preparation et leur application en therapeutique
JP2608788B2 (ja) * 1988-10-31 1997-05-14 大塚製薬 株式会社 精神分裂病治療剤
US5006528A (en) * 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
JP2900130B2 (ja) * 1995-03-16 1999-06-02 大塚製薬株式会社 カルボスチリル誘導体及び該誘導体を含有する精神分裂病治療剤
US7053092B2 (en) * 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
AR032641A1 (es) * 2001-01-29 2003-11-19 Otsuka Pharma Co Ltd Agonista de subtipo de receptor 5-ht 1a.
MY129350A (en) * 2001-04-25 2007-03-30 Bristol Myers Squibb Co Aripiprazole oral solution
MY138669A (en) 2001-09-25 2009-07-31 Otsuka Pharma Co Ltd Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
US8703772B2 (en) 2001-09-25 2014-04-22 Otsuka Pharmaceutical Co., Ltd. Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
AU2003291757A1 (en) * 2002-11-08 2004-06-03 Bristol-Myers Squibb Company Formulations of low solubility bioactive agents and processes for making the same
DE60302139T3 (de) * 2003-01-09 2011-02-24 Otsuka Pharmaceutical Co., Ltd. Verfahren zur herstellung von aripiprazole
WO2004064752A2 (en) * 2003-01-22 2004-08-05 Alkermes Controlled Therapeutics, Inc. Method of preparing sustained release microparticles
CN1809545A (zh) * 2003-06-20 2006-07-26 艾尼纳制药公司 N－苯基－哌嗪衍生物和预防或者治疗5HT2c受体相关疾病的方法
US6987111B2 (en) 2003-08-06 2006-01-17 Alkermes Controlled Therapeutics, Ii Aripiprazole, olanzapine and haloperidol pamoate salts
US20050032781A1 (en) * 2003-08-06 2005-02-10 Elliot Ehrich Methods for administering active agents to CYP 2D6 sensitive patients
PT1675573E (pt) 2003-10-23 2008-12-30 Otsuka Pharma Co Ltd Formulação de iripiprazole injectável estéril de libertação controlada e um processo para a sua preparação
GB0326148D0 (en) 2003-11-10 2003-12-17 Lilly Co Eli Morpholine derivatives
TW200529850A (en) * 2003-12-16 2005-09-16 Teva Pharma Methods of preparing aripiprazole crystalline forms
US7714129B2 (en) * 2003-12-16 2010-05-11 Teva Pharmaceutical Industries Ltd. Methods of preparing anhydrous aripiprazole form II
JP2007517916A (ja) * 2004-02-05 2007-07-05 テバ ファーマシューティカル インダストリーズ リミティド アリピプラゾールを調製するための方法
US7507823B2 (en) * 2004-05-06 2009-03-24 Bristol-Myers Squibb Company Process of making aripiprazole particles
CA2565996A1 (en) * 2004-05-11 2005-11-17 Pfizer Products Inc. Combination of atypical antipsychotics and 5-ht1b receptor antagonists
TW200616608A (en) * 2004-07-09 2006-06-01 Forest Laboratories Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
US20060024362A1 (en) 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
CN101087760B (zh) * 2004-11-18 2011-09-28 斯索恩有限公司 结晶的阿立哌唑溶剂化物
CN101111481A (zh) * 2004-11-18 2008-01-23 斯索恩有限公司 制备结晶阿立哌唑的方法
EP1844792A4 (en) * 2004-12-14 2008-05-21 Shionogi & Co THERAPEUTIC AGENT AGAINST OBSTIPATION
EP1686126A1 (en) * 2005-01-27 2006-08-02 Sandoz AG Salts of aripiprazole
EP2093217B1 (en) * 2005-01-27 2014-03-12 Sandoz AG Process for preparing Form X of aripiprazole
CA2600542A1 (en) * 2005-03-17 2006-09-21 Synthon B.V. Pharmaceutical tablets of crystalline type ii aripiprazole
TWI320783B (en) 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
AU2006239900A1 (en) * 2005-04-22 2006-11-02 Wyeth Therapeutic combinations for the treatment or prevention of psychotic disorders
EP1933814A2 (en) 2005-09-15 2008-06-25 Elan Pharma International Limited Nanoparticulate aripiprazole formulations
WO2007075871A2 (en) * 2005-12-22 2007-07-05 Teva Pharmaceutical Industries Ltd. Processes for reducing particle size of aripiprazole
EP1988899A4 (en) * 2006-02-03 2009-12-30 Reddys Lab Ltd Dr ARIPIPRAZOLE-CO-CRYSTALS
US20060223820A1 (en) * 2006-03-21 2006-10-05 Chemagis Ltd. Crystalline aripiprazole salts and processes for preparation and purification thereof
US7799790B2 (en) * 2006-07-20 2010-09-21 Helm Ag Amorphous aripiprazole and process for the preparation thereof
EP1880714A1 (en) * 2006-07-20 2008-01-23 Helm AG Amorphous Aripiprazole and Process for the Preparation thereof
WO2008047340A1 (en) * 2006-10-19 2008-04-24 Mor Research Applications Ltd. Combined therapies of antipsychotic drugs and tetracyclines in the treatment of psychiatric disorders
EP2079723B1 (en) * 2006-10-24 2012-12-19 Cambrex Charles City, Inc. Process for preparing anhydrous aripiprazole type i
EP1930396B1 (de) * 2006-12-04 2011-07-06 Merck Patent GmbH Furochromanderivate
WO2008144764A1 (en) 2007-05-21 2008-11-27 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using quinolinone based atypical antipsychotic agents
JP4879349B2 (ja) * 2007-07-31 2012-02-22 大塚製薬株式会社 アリピプラゾール懸濁液及び凍結乾燥製剤の製造方法
ATE482691T1 (de) 2008-01-23 2010-10-15 Helm Ag Amorphes aripiprazol und verfahren zu seiner herstellung
DE102008022221A1 (de) 2008-05-06 2009-11-12 Universität des Saarlandes Inhibitoren der humanen Aldosteronsynthase CYP11B2
SG195568A1 (en) * 2008-05-09 2013-12-30 Univ Emory Nmda receptor antagonists for the treatment of neuropsychiatric disorders
CA2727573A1 (en) * 2008-06-25 2009-12-30 Pfizer Inc. Diaryl compounds and uses thereof
PT2445502T (pt) 2009-06-25 2017-09-22 Alkermes Pharma Ireland Ltd Compostos heterocíclicos para o tratamento de distúrbios neurológicos e psicológicos
AU2010293647B2 (en) 2009-09-11 2015-06-25 Otsuka Pharmaceutical Co., Ltd. Therapeutic agent for chronic pain
WO2011030213A1 (en) 2009-09-14 2011-03-17 Jubilant Organosys Limited Improved process for the preparation of 7.(4-bromobutoxy) 3,4-dihydrocarbostyril, a precursor of aripiprazole
US8541404B2 (en) 2009-11-09 2013-09-24 Elexopharm Gmbh Inhibitors of the human aldosterone synthase CYP11B2
NO3034079T3 (es) 2010-11-15 2018-06-09
HRP20240285T1 (hr) * 2011-03-18 2024-05-24 Alkermes Pharma Ireland Limited Farmaceutski pripravci koji sadrže sorbitan estere
WO2012131451A1 (en) 2011-03-30 2012-10-04 Jubilant Life Sciences Limited Process for producing aripiprazole in anhydrous type i crystals
TW201309651A (zh) 2011-06-29 2013-03-01 Otsuka Pharma Co Ltd 阿立哌唑（ａｒｉｐｉｐｒａｚｏｌｅ）無水物Ｂ形結晶微粒子之製造方法
AU2013235519C1 (en) 2012-03-19 2018-04-26 Alkermes Pharma Ireland Limited Pharmaaceutical compositions comprising fatty acid esters
EP2827866B1 (en) 2012-03-19 2023-05-03 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising benzyl alcohol
ES2764383T3 (es) 2012-03-19 2020-06-03 Alkermes Pharma Ireland Ltd Composiciones farmacéuticas que comprenden ésteres de glicerol
WO2013169964A1 (en) * 2012-05-09 2013-11-14 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
KR101571670B1 (ko) 2012-08-08 2015-11-25 주식회사 씨엠지제약 아리피프라졸을 포함하는 경구용 속용 필름 제제
PT2888234T (pt) * 2012-08-21 2018-02-22 Janssen Pharmaceutica Nv Haptenos de aripiprazol e seu uso em imunoensaios
ES2792149T3 (es) 2012-09-19 2020-11-10 Alkermes Pharma Ireland Ltd Composiciones farmacéuticas que tienen estabilidad de almacenamiento mejorada
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
US10525057B2 (en) 2013-09-24 2020-01-07 Otsuka Pharmaceutical Co., Ltd. Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
NZ722077A (en) 2013-12-20 2021-12-24 Agenebio Inc Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
MX376057B (es) 2014-03-20 2025-03-07 Alkermes Pharma Ireland Ltd Formulaciones de aripiprazol que tienen mayores velocidades de inyeccion.
KR20160139704A (ko) 2015-05-28 2016-12-07 주식회사 씨엠지제약 아리피프라졸을 포함하는 경구용 속용 필름 제제, 및 이의 제조방법
CN113264939A (zh) 2015-06-19 2021-08-17 艾吉因生物股份有限公司 用于治疗认知损害的苯并二氮杂环庚三烯衍生物、组合物和方法
US20180170941A1 (en) 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US11505555B2 (en) 2016-12-19 2022-11-22 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
AU2019230014B2 (en) 2018-03-05 2024-11-28 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
US11414425B2 (en) 2018-06-19 2022-08-16 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US20240132513A1 (en) 2022-08-19 2024-04-25 Agenebio, Inc. Benzazepine derivatives, compositions, and methods for treating cognitive impairment
ES2963237A1 (es) * 2022-08-25 2024-03-25 Consejo Superior Investigacion Derivados de quinolina-2(1H)-ona para el tratamiento y prevención de enfermedades neurodegenerativas

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA801037A (en) * 1968-12-10 Regnier Gilbert Procede de preparation de nouveaux derives du piperazino-phenylethanol
GB1021522A (en) * 1963-05-10 1966-03-02 Ici Ltd 2-quinolone derivatives
GB1075156A (en) * 1963-08-27 1967-07-12 Luso Farmaco Inst Substituted piperazines
NL131192C (es) * 1965-06-16
US3362956A (en) * 1965-08-19 1968-01-09 Sterling Drug Inc 1-[(heterocyclyl)-lower-alkyl]-4-substituted-piperazines
US3706749A (en) * 1967-03-30 1972-12-19 Mcneilab Inc N-acyl carbostyrils
US3703522A (en) * 1967-03-30 1972-11-21 Mcneilab Inc Carbostyril derivatives
US3511841A (en) * 1967-05-29 1970-05-12 Sterling Drug Inc 1-((4-,5-,6-,and 7-azaindolyl)-lower-alkyl)- 4-substituted-piperazines
US3635976A (en) * 1967-12-20 1972-01-18 Pennwalt Corp 1 - heterocyclic alkyl-1 2 3 4-tetrahydroquinazolinones and analgesic intermediates thereof
CH514611A (de) * 1968-07-05 1971-10-31 Cassella Farbwerke Mainkur Ag Verfahren zur Herstellung von Derivaten des 2-Oxo-1,2-dihydro-chinolins
DE1795362A1 (de) * 1968-09-19 1972-01-05 Boehringer Mannheim Gmbh Basische AEther und Verfahren zur Herstellung derselben
DE2123923A1 (de) * 1971-05-14 1972-11-23 Boehringer Mannheim Gmbh, 6800 Mannheim 4-eckige Klammer auf omega- (Flavon-7yl-oxy) -alkyl eckige Klammer zu -pigerazin-Derivate und Verfahren zu ihrer Herstellung
BE884459Q (fr) * 1971-05-14 1981-01-26 Boehringer Mannheim Gmbh Derives de la 4-(omega-(coumarine-7-yl-oxy)-alkyl)-piperazine et procede de preparation
DE2335432A1 (de) * 1973-07-12 1975-01-30 Boehringer Mannheim Gmbh 3,4-dihydro-2h-naphthalinon-(1)5-oxy-propyl-piperazin-derivate und verfahren zu ihrer herstellung
US3910924A (en) * 1972-04-13 1975-10-07 Otsuka Pharma Co Ltd 3,4-Dihydrocarbostyril derivatives and a process for preparing the same
JPS517672B2 (es) * 1972-04-13 1976-03-10
US4256890A (en) * 1972-09-14 1981-03-17 Otsukapharmaceutical Co., Ltd. 3,4-Dihydrocarbostyril derivatives and process for producing the same
DE2354145A1 (de) * 1972-11-02 1974-05-16 Sandoz Ag Chinazolin-2(lh)-one und verfahren zu ihrer herstellung
DE2334009A1 (de) * 1973-07-04 1975-01-23 Boehringer Mannheim Gmbh Purin-derivate sowie verfahren zu ihrer herstellung
US3981864A (en) * 1973-09-08 1976-09-21 Eisai Co., Ltd. 1,3-Benzodioxol derivatives
US4117228A (en) * 1973-09-08 1978-09-26 Eisai Co., Ltd. 1,3-benzodioxol derivatives
US4026895A (en) * 1973-09-08 1977-05-31 Eisai Co., Ltd. 1,3-Benzodioxol derivatives
GB1451900A (en) * 1973-10-30 1976-10-06 Sandoz Ltd Quinolin-2-1h-ones
JPS5089376A (es) * 1973-12-19 1975-07-17
US4032528A (en) * 1974-03-25 1977-06-28 Sandoz, Inc. 1,4-substituted-quinolin-2(1h)-ones as cns agents
US3983121A (en) * 1974-07-01 1976-09-28 Council Of Scientific And Industrial Research 1-Substituted 4-(β-2-quinolylethyl)piperazines and 1,2,3,4-tetrahydroquinolyl-ethyl analogues thereof
US3940397A (en) * 1974-11-13 1976-02-24 E. R. Squibb & Sons, Inc. 2-[(Substituted-piperazinyl)alkyl]-1H-benz[de]isoquinoline-1,3(2H)-diones
DE2631317A1 (de) * 1975-07-23 1977-02-17 Sandoz Ag Organische verbindungen, ihre verwendung und herstellung
US3994900A (en) * 1976-01-23 1976-11-30 E. R. Squibb & Sons, Inc. 6-(Or 8)-[[(substituted amino)alkyl]oxy(or thio)]-3,4-dihydro-4-phenyl-2(1H)-quinolinones
ES456325A1 (es) * 1976-02-27 1978-05-01 Sandoz Ag Un procedimiento para la preparacion de nuevos derivados delacido 4-hidroxi-2-quinolinon-3-carboxilico.
US4210753A (en) * 1976-03-17 1980-07-01 Otsuka Pharmaceutical Co., Ltd. Carbostyril compounds
CH619453A5 (es) * 1976-03-17 1980-09-30 Otsuka Pharma Co Ltd
DE2719562C2 (de) * 1976-05-08 1986-05-07 Otsuka Pharmaceutical Co. Ltd., Tokio/Tokyo 3, 4-Dihydrocarbostyrilderivate, Verfahren zu deren Herstellung und Arzneimittel, welche diese enthalten
US4110449A (en) * 1977-05-23 1978-08-29 E. R. Squibb & Sons, Inc. 2-substituted benzisothiazol-3-ones
US4166116A (en) * 1977-11-11 1979-08-28 Canadian Patents And Development Limited Pharmaceutical compositions containing piperazinyl acylhydroxamic acid derivatives to treat inflammation or anaphylactic allergy conditions
DE2960178D1 (en) * 1978-06-06 1981-04-09 Hoechst Ag New substituted phenylpiperazine derivatives, pharmaceutical compositions containing them and process for their preparation
DE2827566A1 (de) * 1978-06-23 1980-01-10 Boehringer Mannheim Gmbh 1,2-dihydro-chinolin-2-on-derivate und verfahren zu ihrer herstellung

Also Published As

Publication number Publication date
CH641350A5 (de) 1984-02-29
FR2421174A1 (fr) 1979-10-26
SU1232144A3 (ru) 1986-05-15
US4734416A (en) 1988-03-29
ES486991A1 (es) 1980-10-01
GB2017701B (en) 1983-03-16
GB2017701A (en) 1979-10-10
ATA235179A (de) 1984-04-15
SE7902794L (sv) 1979-10-01
IT7967674A0 (it) 1979-03-30
JPS54130587A (en) 1979-10-09
SE434945B (sv) 1984-08-27
DK158225B (da) 1990-04-16
PT69422A (en) 1979-04-01
FI70704C (fi) 1986-10-06
AU515531B2 (en) 1981-04-09
DE2912105C2 (de) 1985-08-29
DK128679A (da) 1979-10-26
SU1140687A3 (ru) 1985-02-15
FR2421174B1 (es) 1982-11-19
NO151321B (no) 1984-12-10
ES479134A1 (es) 1980-06-16
CA1117110A (en) 1982-01-26
NL183189C (nl) 1988-08-16
US4824840A (en) 1989-04-25
AT376432B (de) 1984-11-26
FI791034A7 (fi) 1979-10-01
DK158225C (da) 1990-09-17
NL7902514A (nl) 1979-10-02
DE2912105A1 (de) 1979-10-11
NO791049L (no) 1979-10-02
AU4548079A (en) 1979-10-04
MX5862E (es) 1984-08-13
ZA791516B (en) 1980-04-30
BE875174A (fr) 1979-10-01
FI70704B (fi) 1986-06-26
NO151321C (no) 1985-03-20
ES486992A1 (es) 1980-10-01
JPS6223750B2 (es) 1987-05-25
IT1119284B (it) 1986-03-10
DE2953723C2 (de) 1989-01-12
CH641455A5 (de) 1984-02-29

Similar Documents

Publication Publication Date Title
ES486992A1 (es) Un procedimiento para la preparacion de un derivado de car- boestirilo
ES2037752T3 (es) Utilizacion de un derivado de benzoxazol y su procedimiento de preparacion.
ES2037681T3 (es) Procedimiento para preparar nuevos estirilpirazoles, isoxazoles y analogos de los mismos que tienen actividad como inhibidores de 5-lipoxigenasa.
ES2147567T3 (es) El empleo de oxidos de 1,2,4-benzotriazina para la preparacion de un medicamento para el tratamiento de tumores.
ES2036227T3 (es) Ester 2,3,5,6-tetrafluorbencilico del acido (+) 1r-trans-2,2-dimetil-3-(2,2-diclorovinil)-ciclopropancarboxilico.
SE8700498L (sv) Nya farmakologiskt aktiva foreningar
ES2059841T3 (es) Nitro compuestos con actividad insecticida.
AR013815A1 (es) NUEVOS DERIVADOS DEL ACIDO 4-FORMIL-4, 4a, 5, 6, 7, 7a, 8, 8a-OCTAHIDRO- 7-METIL-3-(1-METILETIL)-1,4-METANO-S-INDACEN-3a(1H)-CARBOXILICO, UN PROCESOPARA SU PREPARACION, SU USO EN LA FABRICACION DE UN MEDICAMENTO Y UNA COMPOSICION FARMACEUTICA QUE LOS CONTIENE.
ES2120036T3 (es) Virus recombinantes y su utilizacion en terapia genetica.
ES2133412T3 (es) 2',5'-oligoadenilato-2',3'-ciclofosfatos y 2',5'-oligoadenilatos con actividad sobre el virus papiloma.
FI952734A0 (fi) 2-Amino-6-A-propyyli-amino-4,5,6,7-tetrahydrobentsotiatsolin (Pramipexolin) käyttö lääkeaineena, jolla on antidepressiivinen vaikutus
NO870441D0 (no) Farmasoeytiske preparatformer for stabilisering av alfa- interferon.
DK0552243T3 (da) Anvendelse af interleukin-4 til behandling af faste tumorer
ES2082434T3 (es) Compuestos de tetrametilpiperidina para su utilizacion como estabilizantes para materiales organicos.
JPS54138553A (en) Novel heterocyclic benzamide*its manufacture and psychotropic drug
OA08023A (fr) Nouvelles bis-(4-aminophényl)-sulfones substituées, leur préparation et leur utilisation en tant que médicament.
MX9100341A (es) Compuestos de polipeptido que tiene actividad liberadora de hormona de crecimiento
ES2052811T3 (es) Agente para combatir los insectos y los acaros.
ES2102043T3 (es) Derivados de 22-en-25-oxa en la serie de la vitamina d, procedimiento para su preparacion, preparados farmaceuticos que los contienen, asi como su utilizacion en calidad de medicamentos.
FR2680172B1 (fr) Nouvelles piperazinylalcoyl-3 dihydro-2,3 4h-benzoxazine-1,3 ones-4 substituees, leur preparation et leur application en therapeutique.
ES2108060T3 (es) Composicion de agentes de barrido de halogenos.
ES2010736A6 (es) Procedimiento para preparar nuevos derivados del acido furanuronico.
PE296A1 (es) Derivados de 2-imidazolina-5-onas fungicidas
FI910924A0 (fi) Nya propanaminer, framstaellning av dessa och anvaendning av dessa foer terapeutiska aendamaol, i synnerhet som diarremediciner.
GB1177853A (en) Halogenated Propanes